Structure Therapeutics Appoints Matthew Lang, J.D. as Chief Operating Officer and General Counsel
MWN-AI** Summary
Structure Therapeutics Inc. (NASDAQ: GPCR) announced the appointment of Matthew Lang, J.D. as Chief Operating Officer and General Counsel as of April 14, 2026. Based in San Francisco, Structure Therapeutics is a clinical-stage biopharmaceutical company that focuses on developing innovative oral small molecule therapeutics primarily for metabolic diseases, including obesity. With over 15 years of experience in executive roles across global biopharmaceutical companies, Lang brings extensive expertise in legal affairs, corporate strategy, compliance, and business development.
Raymond Stevens, CEO of Structure Therapeutics, expressed enthusiasm about Lang’s leadership capabilities, noting his proven track record in facilitating organizational growth and transformation, which will be crucial as the company advances its lead asset, aleniglipron, into Phase 3 clinical trials. Prior to this role, Lang was the Chief Legal Officer and Secretary at Metsera, where he played a pivotal role in navigating the company's substantial acquisition by Pfizer. His prior experience also includes significant roles at Lyell Immunopharma and Myovant Sciences, where he contributed to the advancement and commercialization of key therapeutic products.
In his new position, Lang aims to support the operational foundation of Structure Therapeutics while executing its strategic priorities to enhance long-term value. He expressed excitement about joining the company during this critical phase of development for its promising portfolio in the obesity treatment landscape. The company utilizes a next-generation structure-based drug discovery platform, which it believes can deliver accessible therapies to address significant unmet medical needs in chronic metabolic conditions.
In conclusion, Matthew Lang's appointment comes as Structure Therapeutics continues to build its leadership team and advance its innovative therapeutic pipeline.
MWN-AI** Analysis
The recent appointment of Matthew Lang, J.D. as Chief Operating Officer and General Counsel at Structure Therapeutics (NASDAQ: GPCR) presents a potential inflection point for the company, which is poised to advance its promising obesity treatment, aleniglipron, into Phase 3 trials. Mr. Lang brings over 15 years of relevant executive experience across major biopharmaceutical organizations, which could enhance Structure Therapeutics' operational and strategic capabilities.
With Mr. Lang's history of guiding companies through pivotal growth phases—most notably at Metsera during its $10 billion acquisition by Pfizer—investors may view this decision as indicative of an upcoming transformative phase for Structure Therapeutics. His legal expertise combined with experience in business development and commercial strategy may aid in effectively navigating the complexities associated with drug approvals and market entry, especially in a competitive landscape like that of obesity therapies.
As Structure Therapeutics prepares for the critical Phase 3 development of aleniglipron, market sentiment could shift positively if the company demonstrates robust trial outcomes and regulatory advancements. However, investors should remain cognizant of inherent risks as outlined by the company’s forward-looking statements. Factors such as clinical trial outcomes, regulatory approvals, and overall market competition could substantially affect the company’s trajectory and stock performance.
From a market perspective, investors should consider both short-term volatility associated with clinical results and the long-term potential of Structure Therapeutics’ pipeline. Diversifying exposure within the biopharmaceutical sector while staying abreast of aleniglipron's development milestones is advisable. Furthermore, investors should monitor updates regarding Mr. Lang’s strategic contributions as they may offer insights into the company's future operational efficiency and growth prospects. Overall, Structure Therapeutics remains a stock to watch given its innovation-focused approach and strategic leadership.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
SAN FRANCISCO, April 14, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced the appointment of Matthew Lang, J.D. as Chief Operating Officer and General Counsel. Mr. Lang joins Structure Therapeutics with more than fifteen years of executive leadership experience across global biopharmaceutical organizations, with deep expertise spanning legal, corporate strategy, compliance, risk management, and business development.
“Matt is a proven leader with a strong track record of guiding organizations through growth and transformation,” said Raymond Stevens, Ph.D., CEO of Structure Therapeutics. “His experience across global operations, strategic transactions, and commercialization will be critical as we move aleniglipron into Phase 3 and continue to build a world-class leadership team.”
Mr. Lang most recently served as Chief Legal Officer and Secretary at Metsera, Inc., helping to guide the company through its up to $10 billion acquisition by Pfizer. Prior to Metsera, Mr. Lang served as Chief Business and Legal Officer at Lyell Immunopharma, Inc., and held several executive officer positions at Myovant Sciences, where he helped lead the company through Phase 3 clinical development, global approval and commercialization of Myfembree® and Orgovyx®. Mr. Lang also served as the Managing Director and General Manager of Myovant’s European operations in Basel Switzerland where he was responsible for all aspects of Myovant’s ex-US business operations. Earlier in his career Mr. Lang held roles of increasing seniority at Gilead Sciences, Inc., and was an attorney at Dechert, LLP. He received his B.A. in Classical Studies from Queen’s University at Kingston, Canada and his J.D. from the University of Pennsylvania Law School.
“I am excited to join Structure Therapeutics at this important stage as we move into Phase 3 development with one of the most promising late-stage assets in the competitive obesity landscape,” said Mr. Lang. “The Company’s mission and differentiated portfolio represent a compelling opportunity to deliver a complete pipeline of meaningful therapies to patients. I look forward to working with the team to further strengthen the Company’s operational foundation, execute on strategic priorities, and drive long-term value.”
About Structure Therapeutics
Structure Therapeutics is a science-driven clinical-stage biopharmaceutical company focused on discovering and developing innovative oral small molecule treatments for chronic metabolic conditions with significant unmet medical needs. Utilizing its next generation structure-based drug discovery platform, the Company has established a robust GPCR-targeted pipeline, featuring multiple wholly-owned proprietary clinical-stage oral small molecule compounds designed to surpass the scalability limitations of traditional biologic and peptide therapies and be accessible to more people living with obesity around the world. For additional information, please visit www.structuretx.com.
Forward Looking Statements
This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including, without limitation, statements concerning: the Company’s future plans and prospects; and any expectations regarding the potential benefits, tolerability and safety profile, accessibility, scalability, combinability, capability, efficacy, convenience, expected effects and future application of aleniglipron and any other of the Company’s investigational compounds. In addition, when or if used in this press release, the words and phrases “anticipated,” “believe,” “expect,” “may,” “on track,” “plan,” “potential,” “suggests,” “to be,” “to begin,” “will,” and similar expressions and their variants, as they relate to the Company may identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Although the Company believes the expectations reflected in such forward-looking statements are reasonable, the Company can give no assurance that such expectations will prove to be correct. Readers are cautioned that actual results, levels of activity, safety, performance or events and circumstances could differ materially from those expressed or implied in the Company’s forward-looking statements due to a variety of risks and uncertainties, which include, without limitation: risks and uncertainties related to potential delays in the commencement, enrollment and completion of the Company’s planned clinical studies; the Company’s ability to advance aleniglipron, ACCG-2671, ACCG-3535, ANPA-0073, LTSE-2578, and its other therapeutic candidates, obtain regulatory approval of, and ultimately commercialize the Company’s therapeutic candidates; competitive products or approaches limiting the commercial value of the Company’s product candidates; the Company’s ability to fund development activities and achieve development goals; and other risks and uncertainties described in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s latest Annual Report on Form 10-K and future reports the Company may file with the SEC from time to time. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
Investors:
Corey Davis, Ph.D.
LifeSci Advisors, LLC
212-915-2577
cdavis@lifesciadvisors.com
Jun Yoon
Structure Therapeutics Inc.
ir@structuretx.com
Media:
Dan Budwick
1AB
Dan@1abmedia.com
FAQ**
What role will Matthew Lang's experience in global operations and legal strategy play in advancing Structure Therapeutics Inc. GPCR's Phase 3 development of aleniglipron?
How does Structure Therapeutics Inc. GPCR plan to address the competitive landscape in obesity treatment following Mr. Lang's appointment as COO?
What specific therapeutic candidates, apart from aleniglipron, is Structure Therapeutics Inc. GPCR focusing on for regulatory approval and commercialization?
How does the company's innovative oral small molecule pipeline differentiate Structure Therapeutics Inc. GPCR from traditional biologic therapies in the obesity market?
**MWN-AI FAQ is based on asking OpenAI questions about Structure Therapeutics Inc. (NASDAQ: GPCR).
NASDAQ: GPCR
GPCR Trading
-6.69% G/L:
$51.57 Last:
507,458 Volume:
$52.74 Open:
